GlassScriptPhysician profile
Donna D Persaud
NPI 1154873453
$3,834.36
in general payments reported to CMS, 2019-2025
33 companies · $636 in 2025
The $636 reported for 2025 was more than what 79% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $789 · 2022: $688 · 2023: $739 · 2024: $982 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,356.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $505.09 | 2021-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $458.56 | 2024-2025 | Wegovy, Ozempic |
| Amgen INC. | $456.39 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $432.67 | 2021-2024 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $341.55 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $258.94 | 2021-2025 | Lokelma, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.11 | 2021-2022 | |
| Abbvie INC. | $154.62 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $129.90 | 2021-2023 | Verquvo, Belsomra |
| Heartflow, INC. | $101.20 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $89.04 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $66.14 | 2021-2023 | |
| Intra-Sana Laboratories | $63.75 | 2022-2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| E.R. Squibb & Sons, L.L.C. | $62.21 | 2022-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $46.29 | 2021-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $46.26 | 2022 | |
| Janssen Pharmaceuticals, INC | $45.00 | 2021 | |
| Amarin Pharma, INC. | $43.64 | 2022 | |
| Nabriva Therapeutics, Plc | $41.62 | 2021-2022 | |
| Horizon Therapeutics Plc | $38.49 | 2022 | |
| Xeris Pharmaceuticals, INC. | $33.28 | 2023 | Gvoke Hypopen |
| Vifor Pharma, INC. | $32.66 | 2023 | Veltassa |
| Mannkind Corporation | $28.94 | 2023 | Afrezza |
| Azurity Pharmaceuticals, INC. | $27.88 | 2023 | Edarbi |
| Biohaven Pharmaceutical Holding Company LTD. | $27.46 | 2022 | |
| Exact Sciences Corporation | $21.85 | 2025 | The Cologuard Plus Collection Kit |
| Scpharmaceuticals INC. | $19.55 | 2024 | |
| Scilex Pharmaceuticals INC. | $16.76 | 2023 | Ztlido |
| Neurocrine Biosciences, INC. | $16.22 | 2023 | Ingrezza |
| Philips North America LLC | $15.11 | 2023 | |
| Boston Scientific Corporation | $13.90 | 2021 | |
| Pfizer INC. | $13.33 | 2021 | |
| Sun Pharmaceutical Industries INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Persaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.